Cite
Landier W, Bhatia S, Wong FL, et al. Immunogenicity and safety of the human papillomavirus vaccine in young survivors of cancer in the USA: a single-arm, open-label, phase 2, non-inferiority trial. Lancet Child Adolesc Health. 2021;6(1):38-48doi: 10.1016/S2352-4642(21)00278-9.
Landier, W., Bhatia, S., Wong, F. L., York, J. M., Flynn, J. S., Henneberg, H. M., Singh, P., Adams, K., Wasilewski-Masker, K., Cherven, B., Jasty-Rao, R., Leonard, M., Connelly, J. A., Armenian, S. H., Robison, L. L., Giuliano, A. R., Hudson, M. M., & Klosky, J. L. (2022). Immunogenicity and safety of the human papillomavirus vaccine in young survivors of cancer in the USA: a single-arm, open-label, phase 2, non-inferiority trial. The Lancet. Child & adolescent health, 6(1), 38-48. https://doi.org/10.1016/S2352-4642(21)00278-9
Landier, Wendy, et al. "Immunogenicity and safety of the human papillomavirus vaccine in young survivors of cancer in the USA: a single-arm, open-label, phase 2, non-inferiority trial." The Lancet. Child & adolescent health vol. 6,1 (2022): 38-48. doi: https://doi.org/10.1016/S2352-4642(21)00278-9
Landier W, Bhatia S, Wong FL, York JM, Flynn JS, Henneberg HM, Singh P, Adams K, Wasilewski-Masker K, Cherven B, Jasty-Rao R, Leonard M, Connelly JA, Armenian SH, Robison LL, Giuliano AR, Hudson MM, Klosky JL. Immunogenicity and safety of the human papillomavirus vaccine in young survivors of cancer in the USA: a single-arm, open-label, phase 2, non-inferiority trial. Lancet Child Adolesc Health. 2022 Jan;6(1):38-48. doi: 10.1016/S2352-4642(21)00278-9. Epub 2021 Nov 10. PMID: 34767765.
Copy
Download .nbib